Pfizer seeks to correct defect in Lipitor patent
Pfizer files a reissue application with the U.S. Patent Trademark Office to correct a "technical defect" in its patent covering the active enantiomeric form of its blockbuster Lipitor, Pfizer's 2006 financial report indicates. A panel of the U.S. Court of Appeals for the Federal Circuit ruled in August 2006 that a patent claim was invalid on technical grounds. The court also affirms that the basic patent covering Lipitor is valid and thus infringed by Ranbaxy's ANDA for atorvastatin. Ranbaxy, according to Pfizer, filed a petition for a writ of certiorari in January to the Supreme Court to have the Federal Circuit panel's ruling reviewed...
You may also be interested in...
Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.